Truist Boosts Teva (TEVA) Stock Target Amid Pipeline Growth Opportunities

Teva Pharmaceutical Industries Limited (NYSE:TEVA) ranks among billionaire Stanley Druckenmiller’s 10 best stock picks. Truist Securities boosted Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s price target to $38 from $36 on January 28, retaining a Buy rating for the pharma company. The revision comes after Teva’s Q4 2025 results that featured a one-time $500 million Duvakitug Phase 3 landmark contribution.

Truist emphasized that the upcoming enactment of the Inflation Reduction Act and recent inventory loading will make comparisons more difficult for Teva’s Austedo franchise in 2026. The firm also stated that the generics division will have to deal with the loss of about $300 million in sales of gRevlimid during the first quarter of 2026.

Despite these obstacles, Truist believes Teva’s expansion remains in its early stages, with several pipeline drivers anticipated in 2026. The firm also mentioned a possible FDA ruling on Olanzapine LAI in the latter half of 2026, which might open what Truist calls a “de-risked $3B peak sales opportunity” for Teva’s schizophrenia portfolio.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, manufactures, markets, and distributes generic and other medicines & biopharmaceutical products in the US, Europe, Israel, and internationally.

While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.